Suberoylanilide hydroxamic acid (SAHA), which is FDA approved for the treatment of cancer under the trade name Zolinza®, was effective in restoring memory performance in this Alzheimer's disease (AD) model. SAHA was synthesized by Medicilon and was given to mice as 50 mg/kg doses. Injections (10 mL/kg) were given intraperitoneally and were alternated daily between left and right sides of the abdomen. Chronic treatments of SAHA completely restored performance deficits in APP/PS1 mice.

Reference

Mark Kilgore, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 2010 Mar;35(4):870-80. doi: 10.1038/npp.2009.197.